792 related articles for article (PubMed ID: 21674151)
1. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
[TBL] [Abstract][Full Text] [Related]
2. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
Griffiths RR; Richards WA; McCann U; Jesse R
Psychopharmacology (Berl); 2006 Aug; 187(3):268-83; discussion 284-92. PubMed ID: 16826400
[TBL] [Abstract][Full Text] [Related]
3. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.
Griffiths R; Richards W; Johnson M; McCann U; Jesse R
J Psychopharmacol; 2008 Aug; 22(6):621-32. PubMed ID: 18593735
[TBL] [Abstract][Full Text] [Related]
4. High dose psilocybin is associated with positive subjective effects in healthy volunteers.
Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR
J Psychopharmacol; 2018 Jul; 32(7):770-778. PubMed ID: 29945469
[TBL] [Abstract][Full Text] [Related]
5. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.
Garcia-Romeu A; Griffiths RR; Johnson MW
Curr Drug Abuse Rev; 2014; 7(3):157-64. PubMed ID: 25563443
[TBL] [Abstract][Full Text] [Related]
6. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.
Reissig CJ; Carter LP; Johnson MW; Mintzer MZ; Klinedinst MA; Griffiths RR
Psychopharmacology (Berl); 2012 Sep; 223(1):1-15. PubMed ID: 22526529
[TBL] [Abstract][Full Text] [Related]
7. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
8. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA
J Psychopharmacol; 2016 Dec; 30(12):1181-1197. PubMed ID: 27909165
[TBL] [Abstract][Full Text] [Related]
9. Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.
Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR
Psychopharmacology (Berl); 2018 Feb; 235(2):521-534. PubMed ID: 29116367
[TBL] [Abstract][Full Text] [Related]
10. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
MacLean KA; Johnson MW; Griffiths RR
J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
[TBL] [Abstract][Full Text] [Related]
11. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.
Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA
J Psychopharmacol; 2018 Jan; 32(1):49-69. PubMed ID: 29020861
[TBL] [Abstract][Full Text] [Related]
12. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
Carbonaro TM; Johnson MW; Griffiths RR
Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up.
Gukasyan N; Davis AK; Barrett FS; Cosimano MP; Sepeda ND; Johnson MW; Griffiths RR
J Psychopharmacol; 2022 Feb; 36(2):151-158. PubMed ID: 35166158
[TBL] [Abstract][Full Text] [Related]
14. Long-lasting subjective effects of LSD in normal subjects.
Schmid Y; Liechti ME
Psychopharmacology (Berl); 2018 Feb; 235(2):535-545. PubMed ID: 28918441
[TBL] [Abstract][Full Text] [Related]
15. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
Barrett FS; Griffiths RR
Curr Top Behav Neurosci; 2018; 36():393-430. PubMed ID: 28401522
[TBL] [Abstract][Full Text] [Related]
16. A qualitative report on the subjective experience of intravenous psilocybin administered in an FMRI environment.
Turton S; Nutt DJ; Carhart-Harris RL
Curr Drug Abuse Rev; 2014; 7(2):117-27. PubMed ID: 25563444
[TBL] [Abstract][Full Text] [Related]
17. Psilocybin occasioned mystical-type experiences.
James E; Robertshaw TL; Hoskins M; Sessa B
Hum Psychopharmacol; 2020 Sep; 35(5):e2742. PubMed ID: 32573835
[TBL] [Abstract][Full Text] [Related]
18. Psilocybin-Induced Decrease in Amygdala Reactivity Correlates with Enhanced Positive Mood in Healthy Volunteers.
Kraehenmann R; Preller KH; Scheidegger M; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX
Biol Psychiatry; 2015 Oct; 78(8):572-81. PubMed ID: 24882567
[TBL] [Abstract][Full Text] [Related]
19. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
20. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
Lyvers M; Meester M
J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
